Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from Analysts at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) in a research note published on Tuesday morning,Benzinga reports. The brokerage issued a hold rating and a $165.00 price target on the biopharmaceutical company's stock.

Other analysts have also recently issued research reports about the stock. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Royal Bank of Canada decreased their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. Leerink Partnrs cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price target on the stock. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $1,052.90.

Regeneron Pharmaceuticals Stock Up 2.1 %

Shares of Regeneron Pharmaceuticals stock traded up $15.14 during midday trading on Tuesday, hitting $740.01. The company's stock had a trading volume of 978,715 shares, compared to its average volume of 559,383. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 1-year low of $721.08 and a 1-year high of $1,211.20. The stock has a 50-day simple moving average of $844.35 and a 200-day simple moving average of $1,002.55. The firm has a market capitalization of $81.32 billion, a P/E ratio of 17.94, a PEG ratio of 2.19 and a beta of 0.08.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 10 shares during the period. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $26,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.